1. Volume 123, Issue 1, Pages 141-151 (July 2002)
Rapid suppression of hematopoiesis by standard or pegylated interferon-α 
Markus Peck–Radosavljevic, Martina Wichlas, Monika Homoncik–Kraml, Anna Kreil, Harald Hofer, Wolfgang Jessner, Alfred Gangl, Peter Ferenci 
Gastroenterology 
Volume 123, Issue 1, Pages (July 2002)
DOI: /gast
Copyright © 2002 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Study design. Single high-dose IFN-α2a (or IFN-α2b) was administered on day 0, and blood was drawn before and 24 hours after IFN sensitivity testing dose. After 1 week without therapy, IFN-monotherapy (either daily dose IFN-α2b or once weekly pegylated IFN-α2a or pegylated IFN-α2b) was administered between days 7 and 21, and blood was drawn on days 7, 8, 14, and 21. On day 21 (after drawing blood for the final analysis), combination therapy was initiated.
Gastroenterology  , DOI: ( /gast )
Copyright © 2002 American Gastroenterological Association Terms and Conditions

3. Fig. 2
White blood count and viral load. White blood count (WBC), neutrophils, lymphocytes, and viral load during single-dose IFN-α2b (10 Mio IU; day 0), daily IFN-α2b therapy (5 Mio IU/d; days 7–21), once weekly pegylated IFN (days 7–21), and IFN-ribavirin combination therapy (days 22–49); data are given as mean ± SEM (error bars).
Gastroenterology  , DOI: ( /gast )
Copyright © 2002 American Gastroenterological Association Terms and Conditions

4. Fig. 3
Erythropoiesis. Reticulocytes, hemoglobin (HB), and erythropoietin levels (EPO) during single-dose IFN-α2b (10 Mio IU; day 0), daily IFN-α2b therapy (5 Mio IU/day; days 7–21), once weekly pegylated IFN (days 7–21), and IFN-ribavirin combination therapy (days 22–49); data are given as mean ± SEM (error bars).
Gastroenterology  , DOI: ( /gast )
Copyright © 2002 American Gastroenterological Association Terms and Conditions

5. Fig. 4
Peripheral platelet count and thrombopoiesis. β-thromboglobulin (β-TG), thrombopoietin serum levels (TPO), and peripheral platelet count (PPC) during single-dose IFN-α2b (10 Mio IU; day 0), daily IFN-α2b therapy (5 Mio IU/d; days 7–21), once weekly pegylated IFN (days 7–21), and IFN-ribavirin combination therapy (days 22–49); data are given as mean ± SEM (error bars).
Gastroenterology  , DOI: ( /gast )
Copyright © 2002 American Gastroenterological Association Terms and Conditions